Investigation of the Risk of Hypocalcemia in Patients With Rheumatoid Arthritis Who Were Treated for the First Time With Pralia Subcutaneous Injection 60 mg Syringe -Medical Information Database Network-based Cohort Study

DAIICHISANKYO Co., Ltd.0 个研究点目标入组 2,000 人开始时间: 2018年12月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•[The study population]
•Patients who meet all of the following will be included in the study:
•-Disease-modifying anti-rheumatic drugs (DMARDs) have been administered in the data period.
•-Diagnosed rheumatoid arthritis is present between 30 days before DMARDs administration and day of DMARDs administration in the data period.
•[The patient cohort treated for the first time with Pralia]
•Patients who meet the following will be allocated:
•-Pralia has been administered in or after July 3, 2017.
•[The patient cohort not treated with Pralia]
•Patients who meet the following will be allocated:
•-Pralia has not been administered in or after July 3, 2017.

•[The study population]
•Patients who meet the following will be excluded from the study:
•-Pralia was administered in or before June 2, 2017
•[The patient cohort treated for the first time with Pralia]
•Patients who meet any of the following will be excluded:
•-The period from the start day of the observation period to the start day of follow-up is less than 210 days.
•-Ranmark Subcutaneous Injection 120 mg has been administered during the look-back period (the period from 210 days before the start day of follow-up to on the day before the start date of follow-up) or follow-up period.
•-During Look back period, there is no DMARDs administration with diagnosed rheumatoid arthritis between 30 days before DMARDs administration and day of DMARDs administration in the data period.
•-No medical record is present since the start day of follow-up.
•[The patient cohort not treated with Pralia]
•Patients who meet any of the following will be excluded:
•-The period from the start day of the observation period to the start day of follow-up is less than 210 days.
•-Ranmark Subcutaneous Injection 120 mg has been administered during the look-back period or follow-up period.
•-During Look back period, there is no DMARDs administration with diagnosed rheumatoid arthritis between 30 days before DMARDs administration and day of DMARDs administration in the data period.
•-No medical record is present since the start day of follow-up.

发起方

DAIICHISANKYO Co., Ltd.